MedTrace Logo

ZOSTAVAX in Persons Imminently Receiving Chemotherapy for Solid Organ Tumors

NCT02444936 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 22

Last updated 2018-04-06

Study results available
· View outcomes & findings →

Summary

This study evaluates if the shingles vaccine works in those persons that receive it before they receive chemotherapy for solid organ tumors. Half of the participants will receive the ZOSTAVAX shingle vaccine and half of the participants will not received anything.

Conditions

  • Shingles

Interventions

DRUG

ZOSTAVAX

Shingles vaccine

Sponsors & Collaborators

  • Duke University

    collaborator OTHER

  • Louis Stokes VA Medical Center

    lead FED

Principal Investigators

  • David H. Canaday, MD · Cleveland VA

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-05-01
Primary Completion
2018-05-01
Completion
2018-05-01

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02444936 on ClinicalTrials.gov